Medtronic Back to Normal Growth in China, CEO Says

Medtronic Back to Normal Growth in China, CEO Says

Assessment

Interactive Video

Business, Social Studies

University

Hard

Created by

Quizizz Content

FREE Resource

The transcript discusses Medtronic's global business recovery post-COVID, highlighting growth in regions like China, the US, and Europe. It addresses the backlog of elective procedures and the timeline for recovery. Challenges in providing financial guidance due to COVID-19 uncertainties are noted. The transcript also covers Medtronic's product pipeline, including innovations in cardiac rhythm, neuro modulation, and robotic surgery, as well as a breakthrough hypertension therapy.

Read more

3 questions

Show all answers

1.

OPEN ENDED QUESTION

3 mins • 1 pt

What challenges are still present that may affect financial guidance for Medtronic?

Evaluate responses using AI:

OFF

2.

OPEN ENDED QUESTION

3 mins • 1 pt

What are the new therapies that Medtronic is focusing on for growth?

Evaluate responses using AI:

OFF

3.

OPEN ENDED QUESTION

3 mins • 1 pt

How does the new breakthrough hypertension therapy aim to impact healthcare?

Evaluate responses using AI:

OFF